E. Levchenko

发表

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

J. Utikal, A. Hauschild, D. Schadendorf, 2014, The New England journal of medicine.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

M. Zauderer, J. Schellens, D. Fennell, 2019, Investigational New Drugs.

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

R. Collins, C. Gordon, D. Isenberg, 2016, Arthritis & rheumatology.

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.

N. Pavlakis, S. Novello, S. Peters, 2019, Lung cancer.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, The New England journal of medicine.

1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL.

D. Schadendorf, M. Casey, C. Garbe, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

J. Utikal, A. Hauschild, D. Schadendorf, 2015, The Lancet.

Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives.

E. Imyanitov, E. Levchenko, A. Iyevleva, 2020, Critical reviews in oncology/hematology.

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma

A. Hauschild, K. Flaherty, J. Larkin, 2014 .

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European journal of cancer.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The Lancet. Oncology.

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Keunchil Park, N. Reguart, S. Jabbour, 2021, JAMA oncology.

Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.

N. Reguart, S. Jabbour, M. Reck, 2022, Journal of Clinical Oncology.

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

A. Hauschild, S. Puig, J. Goeman, 2018, The Lancet. Oncology.

1235TiP Perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study

M. Tsuboi, H. Wakelee, J. Yang, 2020 .

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

A. Hauschild, D. Schadendorf, K. Flaherty, 2017, European journal of cancer.

KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.

Keunchil Park, N. Reguart, S. Jabbour, 2021 .

Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

A. Hauschild, D. Schadendorf, K. Flaherty, 2020 .

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

J. Utikal, A. Hauschild, D. Schadendorf, 2019 .

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European Journal of Cancer.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

S. Gadgeel, D. Morgensztern, H. Kindler, 2019, Investigational New Drugs.

MAGE-A3 expression in patients screened for the DERMA trial: A phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma.

J. Kirkwood, J. Grob, T. Jouary, 2012 .